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Summary
Background A more transmissible variant of SARS-CoV-2, the variant of concern 202012/01 or lineage B.1.1.7, has 
emerged in the UK. We aimed to estimate the risk of critical care admission, mortality in patients who are critically 
ill, and overall mortality associated with lineage B.1.1.7 compared with non-B.1.1.7. We also compared clinical 
outcomes between these two groups.
Methods For this observational cohort study, we linked large primary care (QResearch), national critical care (Intensive 
Care National Audit & Research Centre Case Mix Programme), and national COVID-19 testing (Public Health 
England) databases. We used SARS-CoV-2 positive samples with S-gene molecular diagnostic assay failure (SGTF) as 
a proxy for the presence of lineage B.1.1.7. We extracted two cohorts from the data: the primary care cohort, comprising 
patients in primary care with a positive community COVID-19 test reported between Nov 1, 2020, and Jan 26, 2021, 
and known SGTF status; and the critical care cohort, comprising patients admitted for critical care with a positive 
community COVID-19 test reported between Nov 1, 2020, and Jan 27, 2021, and known SGTF status. We explored the 
associations between SARS-CoV-2 infection with and without lineage B.1.1.7 and admission to a critical care unit 
(CCU), 28-day mortality, and 28-day mortality following CCU admission. We used Royston-Parmar models adjusted 
for age, sex, geographical region, other sociodemographic factors (deprivation index, ethnicity, household housing 
category, and smoking status for the primary care cohort; and ethnicity, body-mass index, deprivation index, and 
dependency before admission to acute hospital for the CCU cohort), and comorbidities (asthma, chronic obstructive 
pulmonary disease, type 1 and 2 diabetes, and hypertension for the primary care cohort; and cardiovascular disease, 
respiratory disease, metastatic disease, and immuno compromised conditions for the CCU cohort). We reported 
information on types and duration of organ support for the B.1.1.7 and non-B.1.1.7 groups.
Findings The primary care cohort included 198 420 patients with SARS-CoV-2 infection. Of these, 117 926 (59·4%) had 
lineage B.1.1.7, 836 (0·4%) were admitted to CCU, and 899 (0·4%) died within 28 days. The critical care cohort 
included 4272 patients admitted to CCU. Of these, 2685 (62·8%) had lineage B.1.1.7 and 662 (15·5%) died at the end 
of critical care. In the primary care cohort, we estimated adjusted hazard ratios (HRs) of 2·15 (95% CI 1·75–2·65) for 
CCU admission and 1·65 (1·36–2·01) for 28-day mortality for patients with lineage B.1.1.7 compared with the 
non-B.1.1.7 group. The adjusted HR for mortality in critical care, estimated with the critical care cohort, was 0·91 
(0·76–1·09) for patients with lineage B.1.1.7 compared with those with non-B.1.1.7 infection.
Interpretation Patients with lineage B.1.1.7 were at increased risk of CCU admission and 28-day mortality compared 
with patients with non-B.1.1.7 SARS-CoV-2. For patients receiving critical care, mortality appeared to be independent 
of virus strain. Our findings emphasise the importance of measures to control exposure to and infection with 
COVID-19.
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On Sept 20, 2020, a new variant of SARS-CoV-2—known 
as variant of concern 202012/01, or lineage B.1.1.7—was 
detected by the COVID-19 Genomics UK consortium in 
England.1 Lineage B.1.1.7 has multiple changes, including 
an N501Y (Asn501Tyr) substitution in the spike protein 
that enhances binding to the human ACE2 receptor, 
which the virus uses to enter the cell.2 These changes 
have been suggested to result in increased infectivity, 
with initial reports of 50–74% increased transmissibility.3 
Early analyses of mortality linked to diagnostic data have 
suggested that infection with lineage B.1.1.7 might be 
associated with a higher risk of mortality compared with 
infection with other virus variants.4–9 By contrast, a more 
recent study found no association between mortality 
and B.1.1.7 for patients admitted to hospital.10 This new 
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finding, which appears to be discordant from the 
previous ones, has supported the idea that B.1.1.7 is not 
linked to severe disease or death. However, this result 
rather suggests that the effect of B.1.1.7 is different in a 
hospitalised cohort than in the general population and 
does not exclude an increased risk of hospital admission 
with the new lineage. Effects of B.1.1.7 on critical care 
admission or outcomes are still unknown.
In this study, we aimed to explore the association 
between lineage B.1.1.7 and the risk of receiving critical 
care and 28-day mortality, following a positive community 
SARS-CoV-2 test. Additionally, for patients with con-
firmed COVID-19 receiving critical care, we aimed to 
explore the association between lineage B.1.1.7 and 
receipt and duration of organ support in critical care, 
duration of critical care stay, and mortality at the end of 
critical care.
Previous analyses 4–8 had limited adjustment for key 
patient characteristics thought to be associated with 
COVID-19 outcomes. Therefore, the effect of lineage B.1.1.7 
on severe COVID-19 outcomes, receipt of critical care, 
and mortality, when carefully adjusted for key patient 
characteristics, remains unclear. Such adjustments were 
possible in this study, given the availability of patient-level 




For this observational cohort study, we used as main 
datasets the QResearch data platform and Intensive Care 
National Audit & Research Centre (ICNARC) COVID-19 
study data. This analysis is part of a larger study 
protocol.11
QResearch is a high-quality research database based on 
records from 1350 primary care practices in England. 
Established in 2002, QResearch has been used extensively 
for epidemiological research.12 QResearch is one of the 
largest and most representative primary care research 
databases nationally,13 covering approximately 20% of the 
population of England. It has been used for COVID-19 
research to inform the national pandemic response in 
the first pandemic wave.14,15
The ICNARC COVID-19 study data, consisting of 
patients who are critically ill with confirmed COVID-19 
(confirmed at admission to critical care), is hosted on 
the ICNARC Case Mix Programme (the national, high-
quality clinical database for adult critical care) with 
complete coverage of critical care units across England, 
Wales, and Northern Ireland. For this study, only patients 
from England have been included.
The ethics approval for the development and validation 
of QResearch was granted by the East Midlands-Derby 
Research Ethics Committee (reference 18/EM/0400).
Data linkage
To ensure that the QResearch and ICNARC COVID-19 
study data platforms could be used to inform policy and 
planning during the UK COVID-19 epidemic, the primary 
care data and the critical care dataset were linked to other 
databases. The key data linkages for this research 
were COVID-19 testing data (the national registry of 
Research in context
Evidence before this study
A new variant of SARS-CoV-2, variant of concern 202012/01 or 
lineage B.1.1.7, was detected in England in September 2020. 
Lineage B.1.1.7 has been associated with increased 
transmissibility. Early analyses have suggested infection with 
lineage B.1.1.7 might be associated with a higher risk of 
mortality compared with infection with other virus lineages, but 
these analyses had either limited ability to adjust for key 
confounding variables or did not consider admission to a critical 
care unit (CCU). The effects of lineage B.1.1.7 on severe COVID-19 
outcomes remain unclear. We searched PubMed for articles 
published between Sept 1, 2020, and April 15, 2021, containing 
“B.1.1.7”, “B117”, “VOC-202012/1”, “UK variant”, “Kent variant”, 
“sgtf” or “S gene target”, in combination with at least one of 
“mortality”, “ICU”, “fatality”, “severity”, “critical care” or 
“hospital” in any language. We found 36 articles. Many of these 
focused on the sensitivity of lineage B.1.1.7 to vaccine antibodies 
or on the increased transmissibility and mortality of the lineage. 
We found no peer-reviewed publications on the effects of lineage 
B.1.1.7 on critical care admission and mortality and only one 
study that estimated mortality while controlling for patients’ 
demographic and clinical outcomes.
Added value of this study
Our study found a 65% higher risk of 28-day mortality 
associated with infection with lineage B.1.1.7 in patients tested 
in the community compared with patients infected with 
non-B.1.1.7 SARS-CoV-2, when adjusting for key confounding 
variables. The risk of CCU admission for patients with lineage 
B.1.1.7 was double the risk associated with non-B.1.1.7 
SARS-CoV-2 infection. For patients receiving critical care, the 
infecting lineage was not associated with the risk of mortality 
at the end of critical care.
Implications of all the available evidence
Although we observed a higher risk of severe outcomes 
(CCU admission and overall mortality) associated with 
lineage B.1.1.7, once a patient was in a condition severe 
enough to be admitted to CCU, their risk of dying was not 
different between lineages. The higher overall mortality 
and rate of CCU admission associated with lineage B.1.1.7, 
combined with its known increased transmissibility, 
are likely to put health-care systems under additional stress.
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COVID-19 RT-PCR positive test results from Public 
Health England [PHE])—COVID-19 is a notifiable disease, 
and laboratories in England are required to send results of 
all tests to PHE—and Office of National Statistics (ONS) 
COVID-19 mortality data, which includes all deaths due to 
COVID-19 in England. The primary care dataset was 
additionally linked with the ICNARC COVID-19 study 
data, to derive the outcome variable for critical care unit 
(CCU) admission.
Identification of B.1.1.7 by proxy
The molecular diagnosis of SARS-CoV-2 is included as 
part of test results sent to PHE. Lineage B.1.1.7 has a 
deletion of six nucleotides in the S gene that results in 
the deletion of two amino acids at positions 69 and 70 of 
the spike glycoprotein, which leads to S-gene molecular 
diagnostic assay failure (SGTF).
Cycle threshold (Ct) values for the S, N, and ORF1ab 
components of SARS-CoV-2, used to define the 
SGTF status, are available for COVID-19 RT-PCR positive 
tests taken in the community (but not hospital) setting. 
We defined SGTF as any test with non-detectable S gene 
and a Ct of 30 or lower for the N and ORF1ab targets, and 
we defined non-SGTF as any test with detectable S gene 
and Ct of 30 or lower for the N and ORF1ab targets. This 
definition was used by PHE in their report investigating 
the novel SARS-CoV-2 lineage B.1.1.7.5 All other tests were 
defined as inconclusive and excluded from the analysis. 
During the study period, in the UK, more than 
99% of SGTFs were due to lineage B.1.1.7.5 Therefore, 
PCR-positive samples with SGTF were used as a proxy to 
identify the presence (or absence) of lineage B.1.1.7, and 
we used the SGTF status as defined to classify patients 
with the B.1.1.7 lineage and without in each cohort.
Study cohorts and outcomes
We selected a start date of Nov 1, 2020, for the study on 
the basis of the emergence of lineage B.1.1.7, because 
99% of patients with lineage B.1.1.7 were identified after 
this date (appendix p 2). We extracted two cohorts of 
patients from the linked data to explore the association of 
lineage B.1.1.7 with severe COVID-19 outcomes: the 
primary care cohort and the critical care cohort.
The primary care cohort comprised patients in primary 
care with a positive community COVID-19 test reported 
between Nov 1, 2020, and Jan 26, 2021, and known 
SGTF status. For this cohort, we extracted data for the 
following key patient characteristics: age (in years), sex 
(male or female), ethnic group (White, Indian, Pakistani, 
Bangladeshi, other Asian, Caribbean, Black African, 
Chinese, or other ethnic groups), body-mass index 
(BMI; <25, 25 to <30, 30 to <40, or ≥40), comorbidities 
(asthma, chronic obstructive pulmonary disease, type 1 
and type 2 diabetes, and hypertension), smoking status 
(non-smoker, ex-smoker, and light, moderate, or heavy 
smoker), deprivation (quintiles, based on the Townsend 
score), housing category (care home, homeless, or neither), 
household size (one, two, three to five, or six or more people), 
and geographical region (ten regions across England).
The two outcomes of interest for the primary care 
cohort were CCU admission and 28-day mortality, with 
COVID-19 death defined as confirmed or suspected 
COVID-19 recorded on the death certificate, or death 
from any cause within 28 days of a positive COVID-19 
test. For these outcomes, we obtained data from two 
different sources: the ICNARC COVID-19 study data 
platform for CCU admission and ONS mortality data for 
28-day mortality. These two sources had different dates 
for last data updates. Therefore, patients were observed 
until Feb 7, 2021, for the CCU admission outcome (last 
data update of the ICNARC COVID-19 study data 
platform) and until Feb 23, 2021 for the 28-day mortality 
outcome (last ONS data update).
The critical care cohort comprised patients admitted 
for critical care with a positive community COVID-19 test 
reported between Nov 1, 2020, and Jan 27, 2021, and 
known SGTF status. The observational period for this 
cohort was between Nov 1, 2020, and Feb 7, 2021. For 
this cohort, we extracted data for the following key patient 
characteristics: age (in years), sex (male or female), 
ethnic group (White, Indian, Pakistani, Bangladeshi, 
other Asian, Caribbean, Black African, Chinese, or 
other ethnic groups), body-mass index (BMI; <25, 
25 to <30, 30 to <40, or ≥40), deprivation (quintiles, based 
on the Townsend score), comorbidities (cardiovascular See Online for appendix
Figure 1: Flowchart of the primary care cohort and the critical care cohort
ICNARC=Intensive Care National Audit & Research Centre. PHE=Public Health England. SGTF=S-gene molecular 
diagnostic assay failure. *SGTF is used as a proxy for lineage B.1.1.7.
  2 091 828 patients tested positive between
                        Nov 1, 2020, and Jan 26, 2021 (PHE)
12 278 186 patients in primary care (QResearch)
         15 002 patients who were critically ill
                        (ICNARC COVID-19)      
Primary care cohort Critical care cohort
48 039 excluded (not tested in the
               community)
429 926 included in the linked dataset 
381 887 were tested in the community
198 420 had know SGTF status and were
                  included in the primary care cohort
183 467 excluded (no known SGTF status)
117 926 included in
                  the SGTF
                  group*
80 494 included in
                the non-SGTF
                group
2 115 220 patients tested positive between
                     Nov 1, 2020, and Jan 27, 2021 (PHE)
     15 156 patients who were critically ill
                    (ICNARC COVID-19)      
8049 excluded (not tested in the
             community)
15 156 included in the linked dataset 
7107 were tested in the community
4272 had know SGTF status and were include
            in the critical care cohort
2835 excluded (no known SGTF status)
2685 included in the
            SGTF group*
1587 included in the
            non-SGTF group
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disease, respiratory disease, metastatic disease, and 
immunocompromised conditions), depen dency (assis-
tance with activities of daily living: none, some, or all), 
pregnancy (currently pregnant, recently pregnant in 
the past 6 weeks, or not known to be pregnant), 
and cardiopulmonary resuscitation (in 24 h before 
CCU admission). The outcomes of interest for the critical 
care cohort were duration of organ support (respiratory, 
cardiovascular, renal, neurological, and liver) in critical 
care, duration of critical care, and mortality at the end of 
critical care.
We used the primary care cohort to determine the 
association of lineage B.1.1.7 with admission to a CCU after 
a positive test and with the risk of 28-day mortality. We used 
the critical care cohort to determine the association of 
lineage B.1.1.7 with duration of organ support in critical 
care, duration of critical care, and mortality at the end of 
critical care. The patient cohorts are reported according to 
the RECORD guidelines.16
Statistical analysis
We used flexible parametric survival models (Royston-
Parmar model) to estimate the hazard ratio (HR) for 
28-day mortality and admission to CCU comparing 
patients with lineage B.1.1.7 with those without in the 
primary care cohort, and for mortality at the end of 
critical care in the critical care cohort. In all the models, 
we chose degrees of freedom to minimise the Akaike 
information criterion, and we tested possible interactions 
between lineage B.1.1.7 and age, sex, and ethnicity using 
the Wald test. When the proportional hazard assumption 
was not met, a time varying HR was modelled.
For each cohort, we accounted for missing data by 
using multiple imputation by chained equations, which 
generated five imputed datasets. The imputation model 
included age, sex, the outcome of interest (28-day 
mortality, CCU admission, or critical care mortality), and 
all confounding and mediating variables. We fitted 
Royston-Parmar models within each imputed dataset 
and combined them in accordance with Rubin’s rules.
A post-hoc power calculation showed that there is 
80% power at the 0·05 significance level to detect an HR 
higher than 1·04 or lower than 0·96 for admission to CCU 
and higher than 1·09 or lower than 0·91 for mortality at 
the end of critical care in the lineage B.1.1.7 group.
For estimating the HR of 28-day mortality and 
CCU admission in the primary care cohort, the models 
were adjusted for patients’ demographics (age, sex, 
deprivation index, geographical region, ethnicity, 
housing category [care home, homeless, or neither], 
BMI, and smoking status) and comorbi dities (asthma, 
chronic obstructive pulmonary disease, type 1 or 2 
diabetes, and hypertension). Age was modelled by use of 
a restricted cubic spline with four degrees of freedom. A 
random effect frailty term was included to account for 








Admitted to CCU 271 (0·3%) 565 (0·5%) 836 (0·4%)
Deaths within 28 days 334 (0·4%) 565 (0·5%) 899 (0·5%)
Sex
Female 42 976 (53·4%) 61 679 (52·3%) 104 655 (52·7%)
Male 37 518 (46·6%) 56 247 (47·7%) 93 765 (47·3%)
Mean age, years 38·0 (18·1) 37·4 (17·6) 37·7 (17·8)
Age categories, years
18–29 29 122 (36·2%) 42 000 (35·6%) 71 122 (35·8%)
30–39 15 412 (19·1%) 24 012 (20·4%) 39 424 (19·9%)
40–49 13 255 (16·5%) 20 622 (17·5%) 33 877 (17·1%)
50–59 12 604 (15·7%) 18 342 (15·6%) 30 946 (15·6%)
60–69 6318 (7·8%) 8662 (7·3%) 14 980 (7·5%)
70–79 2510 (3·1%) 2994 (2·5%) 5504 (2·8%)
80–89 1022 (1·3%) 1073 (0·9%) 2095 (1·1%)
90–99 251 (0·3%) 221 (0·2%) 472 (0·2%)
Ethnicity
White 49 016 (60·9%) 68 907 (58·4%) 117 923 (59·4%)
Indian 3046 (3·8%) 4900 (4·2%) 7946 (4·0%)
Pakistani 4045 (5·0%) 4323 (3·7%) 8368 (4·2%)
Bangladeshi 2008 (2·5%) 3549 (3·0%) 5557 (2·8%)
Other Asian 1526 (1·9%) 2958 (2·5%) 4484 (2·3%)
Caribbean 400 (0·5%) 1339 (1·1%) 1739 (0·9%)
Black African 1295 (1·6%) 2803 (2·4%) 4098 (2·1%)
Chinese 159 (0·2%) 373 (0·3%) 532 (0·3%)
Other ethnic group 2647 (3·3%) 5162 (4·4%) 7809 (3·9%)
Not recorded 16 352 (20·3%) 23 612 (20·0%) 39 964 (20·1%)
Date of positive test
Nov 1–14, 2020 26 160 (32·5%) 1784 (1·5%) 27 944 (14·1%)
Nov 15–28, 2020 16 509 (20·5%) 2879 (2·4%) 19 388 (9·8%)
Nov 29 to Dec 12, 2020 10 990 (13·7%) 7704 (6·5%) 18 694 (9·4%)
Dec 13–26, 2020 10 847 (13·5%) 23 700 (20·1%) 34 547 (17·4%)
Dec 27, 2020, to Jan 10, 2021 11 368 (14·1%) 46 921 (39·8%) 58 289 (29·4%)
Jan 11–26, 2021 4620 (5·7%) 34 938 (29·6%) 39 558 (19·9%)
Household size
1 person 21 580 (26·8%) 30 432 (25·8%) 52 012 (26·2%)
2 people 16 618 (20·6%) 23 358 (19·8%) 39 976 (20·1%)
3–5 people 36 192 (45·0%) 55 186 (46·8%) 91 378 (46·1%)
≥6 people 6104 (7·6%) 8950 (7·6%) 15 054 (7·6%)
House type
Neither 80 219 (99·7%) 117 549 (99·7%) 197 768 (99·7%)
Care home 226 (0·3%) 271 (0·2%) 497 (0·3%)
Homeless 49 (0·1%) 106 (0·1%) 155 (0·1%)
BMI
<25 43 759 (54·4%) 64 816 (55·0%) 108 575 (54·7%)
25 to <30 10 654 (13·2%) 14 706 (12·5%) 25 360 (12·8%)
30 to <40 4528 (5·6%) 6007 (5·1%) 10 535 (5·3%)
≥40 2540 (3·2%) 3151 (2·7%) 5691 (2·9%)
Not recorded 19 013 (23·6%) 29 246 (24·8%) 48 259 (24·3%)
(Table 1 continues on next page)
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The model used to estimate the association between 
lineage B.1.1.7 and risk of mortality at the end of 
critical care was adjusted by age, sex, ethnicity, BMI, 
deprivation index, severe comorbidities, dependency 
before admission to acute hospital, and geographical 
region. We included a random frailty term to account 
for similarities among patients registered in the same 
CCU. Including the age variable as a linear term rather 
than a restricted cubic spline did not change the results, 
and thus the linear term was included in the final 
model.
Given the timing of emergence of B.1.1.7, some time-
dependent factors exist that might be seen as con-
founders on the association between B.1.1.7 and severe 
outcomes. B.1.1.7 appeared as the number of cases were 
increased—even facilitating this rise, given its higher 
transmissibility.3 The overwhelming of the health 
system, poorer care in very stretched units, and lower 
CCU bed availability are some of the factors that would 
increase mortality, and they might have increased the 
risk of mortality associated with lineage B.1.1.7 if not 
controlled for. To address these factors, we introduced in 
all models the 2-week period in which the test was done 
(overall 28-day mortality and CCU admission) or in 
which the patients had received critical care (critical care 
mortality).
The start time for the mortality and admission to CCU 
analyses using the primary care cohort was the date of a 
positive test. Patients were followed up for 28 days when 
exploring the relative risk of mortality between the B.1.1.7 
and non-B.1.1.7 groups, and followed up to Feb 7, 2021, 
when investigating the relative risk of admission to CCU. 
Individuals who did not receive critical care up to Feb 7 
(for CCU admission analysis) or who did not die within 
28 days (for mortality analysis) were censored on Feb 7 
(for CCU admission analysis) or 28 days after the date of 
a positive SARS-CoV-2 test (for mortality analysis). 
Patients who died during the follow-up period before 
receiving critical care or due to non-COVID-19 causes 
were censored at their date of death. For the analysis of 
mortality at the end of critical care in the critical care 
cohort, the start date was the date of their CCU admission. 
Patients were censored after 28 days, and those who 
survived were censored on their date of discharge from 
critical care. The follow-up period ended on Feb 7, 2021.
Patients with lineage B.1.1.7 became the majority of 
patients with COVID-19 at the end of the study period 
(appendix p 2). This caused patients with B.1.1.7 to have a 
shorter follow-up time and possibly to have their outcome 
not completed by the end of the study period. Therefore, 
in the critical care analysis, we did a sensitivity analysis 
including only patients who had completed their critical 
care outcomes (death or survival at discharge). All 
analyses were re-run including only the complete case 
dataset as an additional sensitivity analysis.
The outcome of 28-day mortality was chosen because 
it was available for all patients irrespective of date of 
admission, by contrast with information on types and 
duration of organ support, for which there was more 
availability in patients who were admitted earlier on in 
the study period. Therefore, to compare the clinical 
characteristics including organ support of patients in 







(Continued from previous page)
Smoking status
Non-smoker 46 182 (57·4%) 65 447 (55·5%) 111 629 (56·3%)
Ex-smoker 14 262 (17·7%) 20 642 (17·5%) 34 904 (17·6%)
Light smoker 6455 (8·0%) 11 276 (9·6%) 17 731 (8·9%)
Moderate smoker 1222 (1·5%) 2050 (1·7%) 3272 (1·6%)
Heavy smoker 429 (0·5%) 702 (0·6%) 1131 (0·6%)
Not recorded 11 944 (14·8%) 17 809 (15·1%) 29 753 (15·0%)
Geographical region in England
East Midlands 1529 (1·9%) 1305 (1·1%) 2834 (1·4%)
East of England 1428 (1·8%) 3912 (3·3%) 5340 (2·7%)
London 13 302 (16·5%) 37 342 (31·7%) 50 644 (25·5%)
North East 4066 (5·1%) 2194 (1·9%) 6260 (3·2%)
North West 26 808 (33·3%) 22 416 (19·0%) 49 224 (24·8%)
South Central 6754 (8·4%) 15 073 (12·8%) 21 827 (11·0%)
South East 3609 (4·5%) 17 945 (15·2%) 21 554 (10·9%)
South West 3966 (4·9%) 3893 (3·3%) 7859 (4·0%)
West Midlands 14 235 (17·7%) 12 140 (10·3%) 26 375 (13·3%)
Yorkshire and Humber 4797 (6·0%) 1706 (1·4%) 6503 (3·3%)
Deprivation quintile
1 (least deprived) 17 606 (21·9%) 22 650 (19·2%) 40 256 (20·3%)
2 17 507 (21·7%) 25 312 (21·5%) 42 819 (21·6%)
3 17 128 (21·3%) 25 327 (21·5%) 42 455 (21·4%)
4 16 054 (19·9%) 23 521 (19·9%) 39 575 (19·9%)
5 (most deprived) 11 622 (14·4%) 20 321 (17·2%) 31 943 (16·1%)
Not recorded 577 (0·7%) 795 (0·7%) 1372 (0·7%)
Comorbidities
Asthma 12 551 (15·6%) 17 241 (14·6%) 29 792 (15·0%)
COPD 875 (1·1%) 998 (0·8%) 1873 (0·9%)
Diabetes type 1 440 (0·5%) 618 (0·5%) 1058 (0·5%)
Diabetes type 2 4101 (5·1%) 5188 (4·4%) 9289 (4·7%)
Hypertension 8473 (10·5%) 11 163 (9·5%) 19 636 (9·9%)
Parkinson 64 (0·1%) 82 (0·1%) 146 (0·1%)
Epilepsy 872 (1·1%) 1278 (1·1%) 2150 (1·1%)
Cerebral palsy 73 (0·1%) 107 (0·1%) 180 (0·1%)
Motor neuron disease <5 (<0·1%) 5 (<0·1%) 8 (<0·1%)
Huntington’s disease <5 (<0·1%) 5 (<0·1%) 6 (<0·1%)
Multiple sclerosis 115 (0·1%) 152 (0·1%) 267 (0·1%)
Myasthenia 20 (<0·1%) 28 (<0·1%) 48 (<0·1%)
Down syndrome 30 (<0·1%) 51 (<0·1%) 81 (<0·1%)
Learning disabilities excluding Down 1343 (1·7%) 1798 (1·5%) 3141 (1·6%)
Data are n (%) or mean (SD). Mortality data is updated up to Feb 23, 2021, and CCU admission data up to Feb 7, 2021. 
Values lower than five are not disclosed for protection of patient confidentiality. BMI=body-mass index. CCU=critical 
care unit. COPD=chronic obstructive pulmonary disease. SGTF=S-gene molecular diagnostic assay failure.
Table 1: Demographics of primary care patients who tested positive in the community between 
Nov 1, 2020, and Jan 26, 2021 (primary care cohort), by lineage status
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restricted our reporting to a matched cohort of patients, 
derived from the critical care cohort. Each patient 
critically ill with B.1.1.7 was matched with a patient 
critically ill without B.1.1.7 admitted to the same unit. 
Only pairs of patients who were admitted within 3 days 
of each other were used in the analysis. If a patient with 
lineage B.1.1.7 was matched with more than one patient 
without B.1.1.7, only one pair was randomly selected. 
Stata/MP, version 16.1, was used for these analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Nov 1, 2020, and Jan 26, 2021, 2 091 828 patients 
had a COVID-19 RT-PCR test result and were recorded in 
the PHE database (figure 1). These patients were linked 
with the 12 278 186 patients registered with participating 
primary care practices in QResearch. This resulted 
in 429 926 primary care patients who had a positive 
COVID-19 RT-PCR test in the study inclusion period, of 
whom 381 887 had been tested in the community. 
SGTF status (as a proxy for B.1.1.7) was identifiable for 
198 420 (51·9%) patients, who constituted the primary 
care cohort (figure 1). Demographics of patients tested in 
the community by whether SGTF status was available are 
shown in the appendix (pp 8–9). In the primary care 
cohort, 899 (0·4%) of 198 420 patients had died of 
COVID-19 within 28 days. Additionally, this cohort was 
linked to the ICNARC COVID-19 study database, 
identifying 836 (0·4%) patients who were admitted for 
critical care before Feb 7, 2021. The community test date 
was after the recorded date of death in 13 patients in the 
primary care cohort and in none of the patients in the 
critical care cohort.
Of 198 420 patients for whom results were available, 
117 926 (59·4%) had SGTF and 80 494 (40·6%) had non-
SGTF (figure 1). SGTF became increasingly dominant 
over the study period (appendix p 2). Patients in the 
SGTF group and the non-SGTF group had broadly 
similar characteristics, with some regional differences; 
however, the SGTF group had a lower proportion of 
patients aged 70 years or older (table 1). In the primary 
care cohort, data were missing for the variables BMI 
(24·3% of patients), smoking status (15·0%), deprivation 
quintile (0·7%), and ethnicity (20·1%; table 1).
565 (0·5%) of 117 926 patients died in the SGTF group 
and 334 (0·4%) of 80 494 in the non-SGTF group. The 
Figure 2: Risk of 28-days mortality and critical care admission in the primary 
care cohort, and mortality in the critical care cohort
SGTF was used as a proxy for lineage B.1.1.7. INARC=Intensive Care National 
Audit & Research. HR=hazard ratio. PHE=Public Health England. SGTF=S-gene 
molecular diagnostic assay failure. *Unadjusted, complete case analysis for the 
period between Nov 1, 2020, and Feb 23, 2021; data sources: QReserach, INARC 
COVID−19 study, and PHE. †Unadjusted, complete case analysis for the period 
between Nov 1, 2020, and Jan 7, 2021; data sources: QReserach, INARC 
COVID−19 study, and PHE. ‡Analysis for the period between Nov 1, 2020, 
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weekly deaths by SGTF status over the study period are 
shown in the appendix (p 2). Figure 2 shows the 
Kaplan-Meier plot for risk of COVID-19 28-day mortality, 
by lineage, for the complete case analysis.
Unadjusted analysis indicated an increase in COVID-19 
28-day mortality for patients in the SGTF group 
(unadjusted HR 1·51, 95% CI 1·29–1·75) compared with 
those in the non-SGTF group, which remained after 
adjustment (1·65, 1·36–2·01). We found no evidence 
of a significant interaction between lineage B.1.1.7 and 
ethnic group (p=0·75), sex (p=0·35), or age group 
(p=0·30; appendix pp 5–6). In total, 836 patients were 
admitted for critical care in the primary care cohort. Of 
these, 565 (0·5%) were in the SGTF group. The weekly 
CCU admissions by SGTF status over the study period 
are shown in the appendix (p 2). Figure 2 shows the 
Kaplan-Meier plot for risk of admission to critical care, by 
SGTF group, for the complete case analysis.
The risk of admission to critical care was higher in the 
SGTF group compared with the non-SGTF group in 
both unadjusted (HR 1·47, 95% CI 1·26–1·70) and 
adjusted (2·15, 1·75–2·65) analyses. However, the 
proportional hazard assumption was not met, so the 
time varying HR was estimated (figure 3). The time 
varying HR was 0·72 (0·40–1·26) 1 day after a positive 
test, 1·89 (1·41–2·53) 5 days after, 3·24 (2·41–4·36) 
15 days after, and 2·41 (1·59–3·63) 20 days after. We 
found no evidence of a significant interaction between 
SGTF group and sex (p=0·95), ethnic group (p=0·49), or 
age group (p=0·23; appendix pp 5–6). Adjusting only for 
the date of positive test did not account for the increased 
risk of admission to CCU in the SGTF group versus the 
non-SGTF group (adjusted HR 1·37, 95% CI 1·14–1·65).
Between Nov 1, 2020, and Jan 27, 2021, 2 115 220 patients 
had a positive COVID-19 RT-PCR test and were recorded 
in PHE. Of these, 15 156 were admitted to CCU in the 
ICNARC COVID-19 study before Feb 7, 2021. Of these 
15 156 patients in CCU, 7107 had a positive COVID-19 
RT-PCR test done in the community (not hospital) 
before CCU admission. SGTF status (as a proxy for 
lineage B.1.1.7) was identifiable for 4272 (60·0 %) patients 
(figure 1), who were included in the critical care cohort. 
Of the 4272 patients in the critical care cohort, 
2685 (62·8%) had SGTF and 1587 (37·2%) had non-SGTF 
(figure 1). Figure 2 shows the Kaplan-Meier plot for risk 
of admission for critical care, by lineage, for the complete 
case analysis.
Patients in the SGTF group tended to be marginally 
younger and be in the lowest BMI category than those of 
the non-SGTF group (table 2). Compared with the non-
SGTF group, acute severity of illness, measured by the 
Acute Physiology And Chronic Health Evaluation II (also 
known as APACHE II) score, tended to be lower in the 
SGTF group, but the proportion receiving invasive 
mechanical ventilation within the first 24 h of critical 
care was higher in the SGTF group. 1851 (68·9%) 
patients in the SGTF group had completed their CCU 
stay at the point of analysis, compared with 1455 (91·7%) 
patients in the non-SGTF group (additional demographic 
character istics are shown in appendix pp 8–9). In the 
critical care cohort, data were missing for the variables 
ethnicity (9·2%) and dependency status before admission 
(9·4%; table 2).
We observed a lower risk of mortality in critical care in 
the SGTF group, in the unadjusted analysis (HR 0·88, 
0·77–0·99). After adjusting for additional confounders 
and date of admission, critical care mortality 
did not differ significantly between the SGTF and 
non-SGTF groups (0·91, 0·76–1·09). We found no 
evidence of a significant interaction between SGTF and 
ethnic group (p=0·34), age group (p=0·53), or sex 
(p=0·95).
In the critical care cohort, 2393 (56%) of patients had a 
follow-up of at least 28 days, and of these, 1315 (54·9%) were 
in the non-B.1.1.7 group. These patients were included in 
the sensitivity analyses, including only patients already 
discharged from critical care (alive or dead), the findings 
of which were consistent with the main analysis 
(characteristics of the critical care cohort restricted to 
those who had completed their critical care stay are 
summarised in appendix pp 8–9). In the primary care 
cohort, a sensitivity analysis for 28-day mortality was not 
required because all patients had complete follow-up to 
28 days. Similarly, for CCU admission outcome, 
185 127 (93·3%) of 198 420 patients in the primary care 
cohort had a potential follow-up period of 20 days and, 
given that 90% of patients who needed critical care were 
admitted within 16 days of the positive test, a sensitivity 
analysis did not seem necessary.
Complete case analyses were all consistent with the 
imputed analyses.
Overall, in the matched cohort of patients who were 
critically ill, organ support receipt was similar between 
the two groups (table 3). Demographic and clinical 
characteristics of patients in the matched cohort are 
shown in the appendix (pp 10–11).
Figure 3: Estimated adjusted HR for critical care admission in the primary care cohort
Adjusted, complete case analysis for the period between Nov 1, 2020, and Jan 26, 2021. Data sources used were 
QReserach, Intensive Care National Audit & Research COVID−19 study, and Public Health England. S-gene 
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Non-SGTF (n=1587) SGTF (n=2685) Full cohort (n=4272)
Mean age, years 59·2 (12·8) 58·1 (12·2) 58·5 (12·5)
Sex
Female 521 (32·8%) 908 (33·8%) 1429 (33·5%)
Male 1066 (67·2%) 1777 (66·2%) 2843 (66·5%)
Ethnicity
White 1149 (72·4%) 1754 (65·3%) 2903 (68·0%)
Indian 63 (4·0%) 106 (3·9%) 169 (4·0%)
Pakistani 96 (6·0%) 128 (4·8%) 224 (5·2%)
Bangladeshi 23 (1·4%) 51 (1·9%) 74 (1·7%)
Other Asian 62 (3·9%) 120 (4·5%) 182 (4·3%)
Caribbean 13 (0·8%) 35 (1·3%) 48 (1·1%)
Black African 13 (0·8%) 47 (1·8%) 60 (1·4%)
Chinese 7 (0·4%) 10 (0·4%) 17 (0·4%)
Other ethnic group 63 (4·0%) 141 (5·3%) 204 (4·8%)
Not recorded 98 (6·2%) 293 (10·9%) 391 (9·2%)
Previous length of hospital stay, days
Mean 2·5 (12·9; n=1580) 3·0 (15·9; n=2640) 2·8 (14·9; n=4220)
Median 1 (0–3; n=1580) 1 (0–3; n=2640) 1 (0–3; n=4220)
Dependency before admission to acute hospital care
Able to live without assistance in daily activities 1378 (86·8%) 2189 (81·5%) 3567 (83·5%)
Some assistance in daily activities 133 (8·4%) 161 (6·0%) 294 (6·9%)
Total assistance with all daily activities <5 (<0·1%) <5 (<0·1%) 9 (0·2%)
Not recorded 72 (4·5%) 330 (12·3%) 402 (9·4%)
Severe comorbidities
Cardiovascular <5 (<0·1%) >10 17 (0·4%)
Respiratory 11 (0·7%) 21 (0·8%) 32 (0·7%)
Renal* 9 (0·6%) 10 (0·4%) 19 (0·4%)
Liver >10 <5 (<0·1%) 9 (0·2%)
Metastatic disease 5 (0·3%) 5 (0·2%) 10 (0·2%)
Haematological malignancy 13 (0·8%) 10 (0·4%) 23 (0·5%)
Immunocompromised 32 (2·0%) 41 (1·5%) 73 (1·7%)
BMI
<25 376 (23·7%) 851 (31·7%) 1227 (28·7%)
25 to <30 439 (27·7%) 649 (24·2%) 1088 (25·5%)
30 to <40 587 (37·0%) 870 (32·4%) 1457 (34·1%)
≥40 185 (11·7%) 315 (11·7%) 500 (11·7%)
CPR within preceding 21 h
In the community 12 (0·8%) 8 (0·3%) 20 (0·5%)
In the hospital 10 (0·6%) 20 (0·7%) 30 (0·7%)
No 1526 (96·2%) 2469 (92·0%) 3995 (93·5%)
Not recorded 39 (2·5%) 188 (7·0%) 227 (5·3%)
Currently or recently pregnant
Currently pregnant 7 (0·4%) 17 (0·6%) 24 (0·6%)
Recently pregnant (within 6 weeks) 5 (0·3%) 19 (0·7%) 24 (0·6%)
Not known to be pregnant 1575 (99·2%) 2649 (98·7%) 4224 (98·9%)
Invasively ventilated within first 24 h
No 1131 (71·3%) 1469 (54·7%) 2600 (60·9%)
Yes 372 (23·4%) 724 (27·0%) 1096 (25·7%)
Not recorded 84 (5·3%) 492 (18·3%) 576 (13·5%)
APACHE II score
Mean 13·9 (5·1; n=1527) 13·0 (4·9; n=2292) 13·3 (5·0; n=3819)
Median 13 (11–16; n=1527) 13 (10–16; n=2292) 13 (10–16; n=3819)
(Table 2 continues on next page)
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Discussion
To our knowledge, this is the first study to report risks 
of admission to CCU and clinical outcomes among 
patients admitted to critical care, comparing patients 
positive for lineage B.1.1.7 with those positive for 
non-B.1.1.7 SARS-CoV-2. Lineage B.1.1.7 became 
dominant over the study period. Using SGTF results as a 
proxy for lineage B.1.1.7, we found a substantially 
increased risk of overall COVID-19 28-day mortality and 
of admission to CCU associated with B.1.1.7, but no 
difference in risk of critical care mortality or organ 
support receipt for patients in CCU.
Previous studies have shown a higher risk of overall 
mortality associated with the B.1.1.7 lineage4–9 and 
no association with mortality in patients admitted to 
hospital.10 Our study is in agreement, showing that, 
once the patient is admitted to CCU, outcomes are 
similar between those in the B.1.1.7 and non-B.1.1.7 
groups. This finding might result from patients in 
either group having similar acute severity of illness at 
the point of admission.
We found a 65% higher risk of COVID-19 28-day 
mortality for patients with lineage B.1.1.7 compared with 
those in the non-B.1.1.7 group. Our study showed that the 
highly prevalent B.1.1.7 infects a population similar to that 
infected with non-B.1.1.7 SARS-CoV-2, albeit with fewer 
patients aged 70 years or older having a positive community 
test for lineage B.1.1.7. Whether this is a true difference in 
who the lineage infects or a difference in exposure or in 
testing remains unclear. An advantage of our study is that 
the primary care cohort had previous recording of a wide 
range of exposures and comorbidities. This allowed us to 
adjust the analysis, controlling for many important 
potential confounders. To attenuate the effect of time-
dependent confounders, we adjusted for an indicator of 
the 2-week period in which the patient tested positive or 
started receiving critical care.
Infection with lineage B.1.1.7 was associated with a 
doubling of the risk of admission to CCU compared with 
infection with non-B.1.1.7 SARS-CoV-2. Although the 
increased infectivity of B.1.1.7 has been reported,2–3 we are 
not aware of previous work examining the risk of 
CCU admission. Adjusting only for the date of positive 
test did not explain this increased risk of CCU admission, 
suggesting that the effect is not explained by time-
dependent factors such as CCU bed availability. Although 
Non-SGTF (n=1587) SGTF (n=2685) Full cohort (n=4272)
(Continued from previous page)
PaO2/FiO2 ratio median 13·2 (10·0–18·2; n=1416) 13·6 (9·8–18·0; n=2056) 13·3 (9·8–18·2; n=3472)
PaO2/FiO2 ratio value
<13·3 kPa (<100 mm Hg) 718 (45·2%) 1022 (38·1%) 1740 (40·7%)
13·3–26·6 kPa (100–200 mm Hg) 585 (36·9%) 873 (32·5%) 1458 (34·1%)
>26·6 kPa (>200 mm Hg) 113 (7·1%) 161 (6·0%) 274 (6·4%)
Not recorded 718 (45·2%) 1022 (38·1%) 1740 (40·7%)
FiO2 [N = 1416/ 2056] median 0·60 (0·45–0·75; n=1416) 0·60 (0·45–0·80; n=2056) 0·60 (0·45–0·80; n=3472)
Data are n (%), mean (SD), or median (IQR). Values lower than five and those denoted as “>10” are not disclosed for protection of patient confidentiality. APACHE II=Acute 
Physiology And Chronic Health Evaluation II. BMI=body-mass index. CPR=cardiopulmonary resuscitation. FiO2=fractional inspired oxygen. PaO2=arterial oxygen partial pressure. 
SGTF=S-gene molecular diagnostic assay failure. *Chronic, irreversible renal disease and being dialysis-dependent before critical care unit admission.
Table 2: Demographic characteristics and medical characteristics and indicators of acute severity observed for patients who were critically ill and tested 







Outcome at end of critical care
Discharged 553 (53·6%) 491 (47·6%) 1044 (50·6%)
Died 289 (28·0%) 262 (25·4%) 551 (26·7%)
Still receiving critical care 189 (18·3%) 278 (30·0%) 467 (22·6%)
Duration of critical care, days
Discharged patients 5 (4–8) 5 (3–9) 5 (3–9)
Deaths 11 (4–16) 11 (6–16) 11 (5–16)
Organ support*
No respiratory support 51 (6·1%) 30 (4·0%) 81 (5·1%)
Advanced respiratory support 401 (47·6%) 340 (45·2%) 741 (46·5%)
Basic respiratory support 672 (79·8%) 635 (84·3%) 1307 (81·9%)
No cardiovascular support 78 (9·3%) 56 (7·4%) 134 (8·4%)
Advanced cardiovascular support 189 (22·4%) 135 (17·9%) 324 (20·3%)
Basic cardiovascular support 750 (89·1%) 688 (91·4%) 1438 (90·2%)
Renal support 142 (16·9%) 101 (13·4%) 243 (15·2%)
Liver support 31 (3·7%) 39 (5·2%) 70 (4·4%)
Neurological support 53 (6·3%) 58 (7·7%) 111 (7·0%)
Duration of organ support, days*
Advanced respiratory support 8 (5–13) 9 (5–14) 8 (5–14)
Total (advanced plus basic) respiratory support 7 (7–11) 7 (4–13) 7 (4–12)
Advanced cardiovascular support 3 (1–4) 2 (1–5) 3 (1–4)
Total (advanced plus basic) cardiovascular support 7 (5–12) 7 (4–13) 7 (4–14)
Renal support 3 (3–6) 5 (3–9) 4 (3–7)
Data are n (%) or median (IQR). Each patient in the SGTF group was matched with a patient in the non-SGTF group 
admitted to the same CCU unit. Only patients who were admitted within 3 days of each other were allowed to be 
matched. For each patient with SGTF status, only one matched set was randomly selected. The matched cohort 
consisted of 2062 patients (761 in the SGTF group and 1031 in the non-SGTF group). CCU=critical care unit. 
SGTF=S-gene molecular diagnostic assay failure. *Among patients who have been discharged or died.
Table 3: Critical care outcomes for the matched cohort of patients who were critically ill with a positive 
test in the community between Nov 1, 2020, and Feb 7, 2021, by lineage
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For QResearch data access 
information see 
www.qresearch.org
this finding raises concerns about future capacity 
planning, it should be interpreted with some caution. For 
example, in our study population, lineage B.1.1.7 
appeared to be more prevalent in younger people than in 
older individuals, and we do not know, with the data 
available, whether this will remain the case as 
lineage B.1.1.7 spreads. The large preponderance of men 
admitted to CCU, despite fewer men having a positive 
COVID-19 RT-PCR test, has been previously reported.17 
Our work showed that this pattern remains with 
lineage B.1.1.7. Both findings are similar to those reported 
for UK data for all CCU admissions, where men were 
admitted in higher proportions than women.17
Our study has some important strengths. It uses 
established, complete, and validated data sources that 
are either the national databases for England (PHE and 
ICNARC COVID-19 study) or a very large representative 
sample (QResearch).14,15,18,19 Outcome data, for both 
patient cohorts, were complete and missing data 
occurred only in some predictor variables. Multiple 
imputation agreed with complete case analyses in both 
cohorts. The use of the national register also minimised 
the risk of misclassification bias; however, mis-
classification bias might still have occurred. A substantial 
limitation of the data available for our work is that the 
determination of SGTF status, as a proxy for B.1.1.7, was 
only possible in just over 50% of patients with a 
community COVID-19 RT-PCR positive test. Patients 
who died after being tested in the community and care-
home residents were less likely to have SGTF status 
identified (appendix pp 3–4). A potential limitation of 
this study is that our analysis was restricted to positive 
tests with Ct of 30 or lower, in line with national 
guidance.5 Selection bias might be introduced if the two 
lineage groups show a striking difference in the Ct 
values at the date of the positive test. However, previous 
work4 suggests that adjusting for Ct values does not 
affect mortality outcomes.
To minimise the risks of changing eligibility over time, 
we restricted our analysis to an 11-week period where 
lineage B.1.1.7 had become noteworthy. We used 
established measures, including critical care mortality 
and measures of critical care severity, such as duration of 
CCU stay and receipt of basic and advanced organ 
support. Our data are very timely, being reported during 
the third pandemic wave in England. We could not 
observe patients who died before being tested. If the 
early risk of death differs between lineages, this could 
introduce bias. As with all observational studies, our 
study remains subject to unmeasured confounding, 
particularly because we are investigating the effects of 
new virus variants during a pandemic, where classi-
fication errors can occur.
Throughout this paper, we have compared lineage B.1.1.7 
with non-B.1.1.7 SARS-CoV-2 by use of the SGTF status as 
proxy for the lineage. It should be acknowledged that the 
non-SGTF group might include other lineages, such as 
501Y.V2 and B.1.351; however, given the prevalence of the 
different lineages in England at the time of the study, it 
seems likely that most non-B.1.1.7 cases represent the 
original virus.
Our study shows increased risk of COVID-19 28-day 
mortality and risk of CCU admission for patients 
who tested positive for lineage B.1.1.7. Combined 
with evidence of increased infectivity, our findings 
emphasise the importance of measures to control exposure 
to and infection with COVID-19.
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